PLX PHARMA WKN: A2DMUN ISIN: US72942A1079 Kürzel: 1D5A Forum: Aktien Thema: Hauptdiskussion
0,0000 USD
±0,00 %±0,0000
30. Sep, 00:20:00 Uhr,
Nasdaq OTC
Kommentare 102
Summer.76,
12.11.2021 13:15 Uhr
0
PLx Pharma EPS beats by $0.09, beats on revenue
https://seekingalpha.com/news/3769940-plx-pharma-eps-beats-0_09-beats-on-revenue?utm_source=webull.com&utm_medium=referral
• PLx Pharma (NASDAQ:PLXP): Q3 Non-GAAP EPS of -$0.37 beats by $0.09; GAAP EPS of -$0.80 misses by $0.34.
• Revenue of $6.6M beats by $2.5M.
nionus,
15.11.2021 19:28 Uhr
0
https://zolmax.com/investing/plx-pharma-inc-nasdaqplxp-shares-purchased-by-vanguard-group-inc/6508739.html
nionus,
07.12.2021 19:03 Uhr
0
https://seekingalpha.com/news/3777793-plx-pharma-gains-after-raymond-james-upgraded-on-valuation
nionus,
07.02.2022 7:25 Uhr
2
https://youtu.be/O_OCb5owR7g
TV Werbespot der aktuell in den USA läuft.
Summer.76,
11.03.2022 16:12 Uhr
0
https://www.biospace.com/article/releases/plx-pharma-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-update/?s=110
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules
• Total Net Sales of $8.2 Million in Last Five Months of 2021
• Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021
• Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022
• GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.73)
• Cash & Cash Equivalent Balance of $69.4 Million at Year-End 2021
Summer.76,
12.11.2021 13:12 Uhr
0
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
https://finance.yahoo.com/news/plx-pharma-inc-reports-third-115000911.html
-- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites --
-- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE --
-- Third quarter 2021 net loss was ($0.80) per share and adjusted non-GAAP net loss per share of ($0.37) --
-- Early feedback received from consumers and healthcare professionals is very positive -–
Summer.76,
04.11.2021 17:12 Uhr
0
PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules
https://finance.yahoo.com/news/plx-pharma-inc-announces-scientific-135000021.html
-- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition --
-- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with
VAZALORE 325 mg --
...
nionus,
01.11.2021 19:40 Uhr
0
https://www.analystratings.com/articles/jmp-securities-remains-a-buy-on-plx-pharma-plxp/
Summer.76,
29.10.2021 15:11 Uhr
0
PLx Pharma Inc. Provides VAZALORE Launch Update
https://www.globenewswire.com/news-release/2021/10/29/2323515/0/en/PLx-Pharma-Inc-Provides-VAZALORE-Launch-Update.html
-- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites --
-- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received --
-- Third quarter 2021 earnings and business update conference call scheduled for November 12th --
...
nionus,
26.10.2021 22:22 Uhr
0
https://www.infrastructurene.ws/2021/10/26/ischemic-cerebral-stroke-market-2021-major-eminent-key-players-growing-with-tremendous-speed-touching-new-industry-heights-forecast-by-2027/
nionus,
14.10.2021 21:57 Uhr
0
https://ir.plxpharma.com/news-releases/news-release-details/plx-pharma-inc-issues-statement-recent-usptf-recommendations
Summer.76,
14.10.2021 19:37 Uhr
0
https://www.globenewswire.com/news-release/2021/10/14/2314570/0/en/PLx-Pharma-Inc-Issues-Statement-on-Recent-USPTF-Recommendations-on-Aspirin-Therapy-for-Primary-Prevention-of-Cardiovascular-Disease-PLx-s-VAZALORE-Specifically-Indicated-for-Second.html
PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx’s VAZALORE Specifically Indicated for Secondary Prevention
Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke
...
Summer.76,
14.10.2021 19:18 Uhr
0
Könnte damit zusammen hängen:
Kehrtwende in US-Medizin: US-Gremium empfiehlt Aspirin nicht mehr vorbeugend
https://www.n-tv.de/wissen/US-Gremium-empfiehlt-Aspirin-nicht-mehr-vorbeugend-article22863272.html
https://www.washingtonpost.com/lifestyle/2021/10/12/low-dose-aspirin-heart-attack-stroke/
nionus,
14.10.2021 19:16 Uhr
0
Grund ist wohl der folgende Artikel,andere News gab es nicht.
Ich halte das für eine Überreaktion. Spannend wird's wenn die nächsten Zahlen veröffentlicht werden:
https://www.washingtonpost.com/lifestyle/2021/10/12/low-dose-aspirin-heart-attack-stroke/
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | für alle, die es ehrlich meinen beim Traden. | ||
2 | GAMESTOP Hauptdiskussion | +30,48 % | |
3 | Das neue Dax Prognose Forum | +0,47 % | |
4 | Aktien und Saunaclub alla Luci | ||
5 | TUPPERWARE Hauptdiskussion | +25,96 % | |
6 | Jaguar Health für Investierte und Interessierte | +1,03 % | |
7 | Canopy Hauptforum | -1,40 % | |
8 | PAYPAL Hauptdiskussion | -2,20 % | |
9 | Nio für normale Kommunikation | -0,77 % | |
10 | Hims & Hers Health Registered (A) Hauptdiskussion | -9,55 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | GAMESTOP Hauptdiskussion | +30,48 % | |
2 | TUPPERWARE Hauptdiskussion | +25,96 % | |
3 | Jaguar Health für Investierte und Interessierte | +1,03 % | |
4 | Canopy Hauptforum | -1,40 % | |
5 | PAYPAL Hauptdiskussion | -2,20 % | |
6 | Nio für normale Kommunikation | -0,77 % | |
7 | Hims & Hers Health Registered (A) Hauptdiskussion | -9,55 % | |
8 | Nantkwest / Immunitybio -> IBRX | -1,76 % | |
9 | PLUG POWER Hauptdiskussion | +11,43 % | |
10 | NVIDIA Hauptdiskussion | +2,40 % | Alle Diskussionen |